[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100169384":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":31,"locations":37,"responsibleParty":59,"collaborators":31,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":31,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":31,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":86,"whyStopped":31,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Astellas Pharma Inc","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm A","EXPERIMENTAL","mirabegron",[13],"Drug: mirabegron OCAS",{"label":15,"type":16,"description":17,"interventionNames":18},"Treatment Arm B","PLACEBO_COMPARATOR","matching placebo",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","mirabegron OCAS","oral",[9],[27],"YM178 OCAS",{"type":22,"name":29,"description":24,"armGroupLabels":30,"otherNames":31},"Placebo",[15],null,[33],{"name":34,"affiliation":35,"role":36},"Clinical Study Manager","Astellas Pharma Europe B.V.","STUDY_CHAIR",[38,50],{"facility":39,"status":31,"city":40,"state":31,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":31},"Kendle Nederland","Utrecht","358 CJ","Netherlands","NL",{"type":45,"coordinates":46},"Point",[47,48],5.12222,52.09083,{"lat":48,"lon":47},{"facility":51,"status":31,"city":52,"state":31,"zip":53,"country":42,"countryCode":43,"cosmosGeoPoint":54,"geoPoint":58,"contacts":31},"Pharma Bio Research","Zuidlaren","9470 AE",{"type":45,"coordinates":55},[56,57],6.68194,53.09417,{"lat":57,"lon":56},{"type":60,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100169384","phase-1-to-evaluate-the-blood-and-urine-concentration-and-the-safety-and-tolerability-of-increasing-repeated-doses-of-mirabegron-ym178-ocas-in-healthy-young-and-elderly-males-and-healthy-young-and-elderly-females-100169384",false,"NCT01478503","To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females","Double-blind, Randomized, Placebo-controlled, Dose-escalating, Exploratory Study to Investigate the Pharmacokinetics, Safety and Tolerability of Multiple Doses of YM178 OCAS-M in Healthy Young Male and Female Subjects and Healthy Elderly Male and Female Subjects","Inclusion Criteria:\n\n* Healthy young subjects aged 18-55 years (inclusive)\n* Healthy elderly subjects aged 65-80 years (inclusive)\n* Body weight between 60.0 and 100.0 kg (male) or between 50.0 and 90.0 kg (female), and Body Mass Index between 18.0 and 30.0 kg\u002Fm2\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to β-adrenergic receptor agonists or any components of the formulation used\n* Any of the liver function tests (i.e. ALT, AST and bilirubin) above the upper limit of normal at repeated measures\n* Any clinically significant history of any other disease or disorder - gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological, dermatological, psychiatric or metabolic as judged by the medical investigator.\n* Any clinically significant abnormality following the investigator's review of the pre-study physical examination, electrocardiogram (ECG) and clinical laboratory tests\n* Subjects taking β blockers or β agonists\n* Use of any prescribed or Over-the-counter (OTC) drugs (including vitamins, natural and herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the Clinical Unit, except for occasional use of paracetamol (up to 3 g\u002Fday)\n* Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampicin) in the 3 months prior to admission to the Clinical Unit\n* Donation of blood or blood products within 3 months prior to admission to the Clinical Unit\n* Any use of drugs of abuse, or smoking of more than 10 cigarettes (or equivalent) or more than 21 units of alcohol per week within the 3 months prior to study\n* Participation in any clinical study within 3 months or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study",true,"ALL","18 Years","80 Years",{"count":73,"type":74},96,"ACTUAL","INTERVENTIONAL",[77],"PHASE1","The study aimed to compare age and gender differences for increasing doses of mirabegron when given to healthy young and elderly males and healthy young and elderly females.",[80,81],"Pharmacokinetics","Healthy Subjects",[80,83,84,85],"Mirabegron","Phase 1","Dose-Escalation","COMPLETED","2013-07-01",{"date":89,"type":90},"2013-07-02","ESTIMATED",{"date":92,"type":31},"2005-05",{"date":94,"type":74},"2005-10",{"name":5,"class":6},2]